Both methotrexate and leflunomide have been shown to have efficacy in treating active
polyarticular JIA, in clinical trial testing. Methotrexate has been tested more extensively, has
slightly higher efficacy and the advantage of being able to adjust the dose more easily as well as
administer it through an injection when needed. It is known to have good efficacy in patients
with uveitis, whereas leflunomide has not been tested in this situation. Most commonly,
methotrexate is the first second-line, or disease modifying agent recommended, and
leflunomide is recommended when methotrexate is not tolerated.